The father and son in the development zone have been praised by Chinese people
- Categories:Company News
- Author:
- Origin:Yizhuang Time News
- Time of issue:2022-05-23
- Views:968
(Summary description)In the new medical insurance drug list released in September this year, the emergence of four anti-tumor monoclonal antibody drugs has aroused people's attention to monoclonal antibody drugs.
The father and son in the development zone have been praised by Chinese people
(Summary description)In the new medical insurance drug list released in September this year, the emergence of four anti-tumor monoclonal antibody drugs has aroused people's attention to monoclonal antibody drugs.
- Categories:Company News
- Author:
- Origin:Yizhuang Time News
- Time of issue:2022-05-23
- Views:968
In the new medical insurance drug list released in September this year, the emergence of four anti-tumor monoclonal antibody drugs has aroused people's attention to monoclonal antibody drugs.
As we all know, monoclonal antibody drugs are the most difficult and high-level fields in biological medicine. Its development level has become an important symbol to measure the overall level of a country's biomedical development.
With the emergence of this news, the names of two people have been mentioned constantly, namely Bai Xianhong and Bai Yi.
One of them has founded a "rare top biotechnology enterprise with innovative ability in China" that has been praised by American media. Taixinsheng, a monoclonal antibody drug successfully industrialized for the treatment of malignant tumors. It is also the only product "created in China" among the four anti-tumor drug lists of medical insurance. It fills the gap in the field of humanized monoclonal antibody in China. A new McAb drug R&D enterprise was listed in the "Top 100 Black Science and Technology Enterprises in China" within 5 years. He took the lead in developing a new biological class I drug for treatment of type II diabetes - Exendin-4 immune fusion protein, and won the gold medal of the 10th Beijing Invention and Innovation Competition.
They are father and son. Two generations won 34 new drug patents. In the first half of this year alone, four new drug certificates were obtained. Composed a song of pursuing dreams that is persistent and inherited.
Father stuck to his guns and sent the monoclonal antibody to the medical insurance
It seems to be the most common and rugged. It is as easy as it is hard.
At 6:00 p.m. on September 27, when the lights in Biotech's office went out one by one. Bai Xianhong, who is about to turn 70, is busy reading the report of the day. At the other end of his desk is a pot that is cooking dumplings in hot air.
He hasn't had supper yet. He is going to have an online class at 7:30. It's too late to go home. Although the journey home is only 10 minutes' drive. Before that, he would also like to discuss with the executives about the change of sales volume of Taixinsheng, which just entered the medical insurance in September.
This is the result of his five years of hard work. It is also his dream to let more people benefit from the treatment of innovative drugs.
In the human war of conquering cancer, the Chinese people have created a record since 2008. In that year, Baitai Biology led by Bai Xianhong lasted for 8 years. Taixinsheng (nituzumab), a humanized monoclonal antibody for cancer, was successfully marketed. Taixinsheng was called "biological missile" since he was born, because it can accurately "snipe" cancer cells. The significance of this drug lies in that it is a breakthrough in the field of biological targeted drug treatment of cancer that the Chinese people have made, which is comparable to the world's advanced level.
"The price of one gram of gold is 300 yuan, while the price of one gram of Taixinsheng antibody is 70000 yuan, more than 200 times that of gold." These figures vividly describe the scientific and technological content of Baitai. In the first year of listing, the company achieved sales revenue of hundreds of millions of yuan. Up to now, Taixinsheng has exceeded 2 billion yuan in the domestic drug market in public hospitals.
However, Bai Xianhong was not satisfied with this achievement. At the beginning, he aimed to develop new drugs. Then Bai Xianhong's desire is to let more people use it after the successful research and development of Taixinsheng.
However, it is not easy to enter medical insurance for more people to use. First of all, many researchers and even employees feel that they should not enter the price threshold of medical insurance. Because this means that the company's profits will be greatly reduced. The average selling price dropped from 3680 yuan to 1700 yuan, a drop of 53.8%.
"The goal of innovation is to benefit human life." Bai Xianhong insisted on lowering prices to benefit more cancer patients.
In order to achieve this goal, he took the initiative to innovate in spite of his advanced age. 25% of the enterprise's income is invested in clinical work. He continues to expand the scope of Taixinsheng's indications. At the same time, the EGF vaccine developed by Taixinsheng for cancer treatment and the innovative drug "Irizumab" for the treatment of rheumatoid and psoriasis have also entered the clinic.
Inheritance of sons, reproduction of Teke legend
It was Bai Xianhong's early goal to be China's Genentech. Genentech is the abbreviation of American Genetic Engineering Technology Company. At present, it is the second largest biotechnology company in the world after Amgen in scale and strength. It is considered as the founder of biotechnology industry.
So in 2011, he founded Dongfang Baitai. This is an enterprise 100% owned by China. The company focuses on the research and development of innovative drugs with independent intellectual property rights. Bai Yi, his son who returned from studying abroad, took over his baton.
He lived up to his father's expectations. After 6 years of establishment, Dongfang Baitai has not only established a senior technology research and development team of nearly 200 people. It has a complete set of key technologies, equipment, platforms and systems for antibody research and development. More than 20 R&D pipelines for major diseases such as anti-tumor, diabetes and autoimmune diseases have been launched. It has undertaken seven national major new drug development projects.
From the second half of last year to the beginning of this year, Dongfang Baitai has successively obtained the diabetes treatment drug JY09 Exendin-4 fusion protein, "recombinant humanized anti VEGF monoclonal antibody injection, anti vascular endothelial growth factor (VEGF) humanized antibody drug JY028 and anti tumor necrosis factor- α (TNF- α) Approval documents for clinical trials of four drugs of whole human antibody drug JY026. Dongfang Baitai has become a leader in the field of monoclonal antibody in China.
In particular, its JY09 Exendin-4 fusion protein, which is used to treat type II diabetes, has been recognized as a new drug of national biological products. The drug was injected for 7-10 days, which broke through the technical bottleneck of frequent injections of traditional GLP-1 receptor agonists, from three injections a day to once every 7-10 days. It greatly alleviates the pain and inconvenience of patients. It can steadily control the blood sugar level of patients, reduce the risk of hypoglycemia, and improve the safety of drug use. It has become another "blockbuster" in the field of biomedicine in China. It not only won the gold medal of the Beijing Innovation Competition, but also won patents from more than 20 countries in Europe and the United States.
Compared with his father Bai Xianhong, Bai Yi pays more attention to the export of Chinese new drugs to the world stage. When Bai Xianhong was eating dumplings, the Capital Airport was 50 kilometers away. Bai Yigang, the general manager of Dongfang Baitai, who is committed to developing the South American market, stepped off the plane.
He has gained a lot this time, and has basically finalized the industrialization plan of JY09 Exendin-4 fusion protein in South America.
Bai Yi said that he liked Madame Curie's famous saying: We should turn life into a scientific dream, and then turn the dream into reality.
Father and son work together to forge Chinese antibody business card
In the core area of the development zone, the 27 acres industrialization base of Dongfang Baitai has now been completed.
In fact, last year and the year before last, many people found Bai Xianhong and his son. They advised them to turn the industrial base into a science and technology park. In this way, the capital can be withdrawn quickly and the investment is less than that of industry. The father and son resolutely rejected these proposals. The industrial base will be built in accordance with GMP standards. They hope to realize industrialization and shorten the marketing cycle of new drugs as soon as they complete the clinical work.
"Our goal is to improve the market share and competitiveness of China's antibody drugs in the world's advanced antibody drugs, and create a global focus on biomedical innovation." Bai Xianhong said frankly. The company now has dozens of Chinese invention patents. There are many international PCT patents, covering the United States, Europe, Japan, South Korea, Eurasia and other countries and regions; More than 40 registered trademarks have been approved.
"It's not too far to make dreams come true." Bai Yi is obviously more optimistic than his father. In the next five years, we will once again have an innovative drug on the market that attracts the attention of the world. When he said this, his eyes were firm. On his desk was the first prize of Beijing Science and Technology Progress Award that Baitai just won in May this year.
Scan the QR code to read on your phone
推荐新闻
Follow us

Follow the official WeChat official account
Or search "Oriental Baitai"
More exciting waiting for you!
Address: No. 2, Rongjing East Street, Beijing Economic and Technological Development Zone
Tel.: 010-51571019
Email: ebt@east-bt.com
Copyright 2021 Beijing Dongfang Baitai Biotechnology Co., Ltd SEO 京ICP备********号